{"name":"Neurovance, Inc.","slug":"neurovance-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"EB-1020 400 mg","genericName":"EB-1020 400 mg","slug":"eb-1020-400-mg","indication":"Other","status":"phase_1"}]}],"pipeline":[{"name":"EB-1020 400 mg","genericName":"EB-1020 400 mg","slug":"eb-1020-400-mg","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMinAFBVV95cUxQTXNOeG91QXB2TmUyc3loQ3ZZSE1DWWpPMHFXdVZpNzR1R3hSejF5UGRoX3BlM0hxRXByOTZBcW43LWs1N1RtLXgzQmQ1RzRGVkRZM09tQ2VESXZKbm1hWkRQMmlSc0ZBV0h5aFd4RmlOWXhzNGU2WHpDM3BPVWpqLUdsRjVXb3pDZHZlTWZ5YWJrUjZLOVNoSUxUbG_SAaMBQVVfeXFMT3I5WVFfOUp2YmdkeFNBd1UzaEdya2tOR2xOUER4UWwtV0pReE0ySzRremxaNzNGRkg2dzRSblc5TzdzWmRtdzJfOC1RejBBR19FZm54aVVMelJBWm1NYUkzcjVYSXpyN040Uk9Qc1BPZXZlamhrNG1jNTBRRm5IVHV1S05senJYWmdFTmphTE1oMWtVckIzV3NZZGN4THZSZm0zYw?oc=5","date":"2024-10-04","type":"deal","source":"The Hindu","summary":"Lupin arm buys nine brands in South Africa - The Hindu","headline":"Lupin arm buys nine brands in South Africa","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqwFBVV95cUxQRnhrSEhnMkhDZHBEWFppM3VlZDM2Nk54ek95dUxkVlRrTWNXM1J5bndLQ21xdnZWcUI4X2pRUW92ZXV4VXlkb0dTSUFMV19POWVCX2xFV3oyaXNHT0hhTkZUR1l0TUQ1Q3BVTm9kQWhlb05BeUI1czRlQ3N5X3pYMWZySVluOTViMEY0RmZROHpQSW1jU3lQOU9qTFRBLS1QUVZrOENpVGtaa1k?oc=5","date":"2024-06-14","type":"pipeline","source":"citybiz","summary":"Intellia Therapeutics Apppoints Brian Goff to its Board of Directors - citybiz","headline":"Intellia Therapeutics Apppoints Brian Goff to its Board of Directors","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiYkFVX3lxTE1NNzVMQ01scFVmWVNzeTY3OHhEbUVMVFFZX2tVTWVZZmhEQ09rM1dDWFY1cHBvT29rcTV1RjVsLUdKTThTWXp2b0VaWFRNWXVwTWJNSng2aUUwcHB4eXlsZ25R?oc=5","date":"2020-01-06","type":"deal","source":"ACS Publications","summary":"Otsuka to acquire Neurovance - ACS Publications","headline":"Otsuka to acquire Neurovance","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMingFBVV95cUxQWS15aXZOUnJyTEY5cEVhTUxRUXgycmw3ek1jeFdRMHJfS01PQ1F2TnBtVHFQd0tPZk5jSlJ1bnBaNmhmcGQ3X28xZHRLb1NKaExydDBBR1hfZ1Z6c2J2R1pBWjdFWGVySVJTZkFHQi1LNXY5RXQtM3FXaDRGeVJxeGJoQ2dHanZQT2p4LUpwa1d3eUE3NTJDUmw0cHFSZw?oc=5","date":"2017-05-24","type":"pipeline","source":"BioPharma Dive","summary":"Under new CEO, Alexion continues overhaul of leadership - BioPharma Dive","headline":"Under new CEO, Alexion continues overhaul of leadership","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMidEFVX3lxTE9BdGhUck55RjJnSG1Zc3JRbjdGVFhyYVlLbFV4Sk9Ya19IUmFxb0Vpc0ZyVTg3SmRMQ1JRWmIyaTQwSkJ2T2R1bVFzWUNzZTNaeGdRV0t5eU41cUZGZTRSLUZCdEdwSndNX2JzWUNJNFV4X1NB?oc=5","date":"2017-03-13","type":"deal","source":"C&EN","summary":"Otsuka to acquire Neurovance - C&EN","headline":"Otsuka to acquire Neurovance - C&EN","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiigFBVV95cUxQZ09FWkw4MHZBTGxQVW8xQ2kzNFVGSFJ2bHc1SF9iUTVxQWdhY1FmYWVUN0s0d3BEbW5Cb1o4aWVsSU1lUGRmaGRsaTVVYThHNDBGb080b0dfR0xEOG9KaUUwZDE4b3dvS2pMRUxKYzFMNTNzMVdhVllpb29feWxwQm1qdVcxUS1YYUE?oc=5","date":"2017-03-06","type":"deal","source":"BioPharma Dive","summary":"Otsuka acquires ADHD drug in $100M deal for Neurovance - BioPharma Dive","headline":"Otsuka acquires ADHD drug in $100M deal for Neurovance","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiAFBVV95cUxPaGlhOE5aLTlrbmFGMHVKdl81QmloTWtoekNKVXl6em0xYkdaZV9CV0t2N2o0djVuejNORmhfUUZuYkJsdmlEVWp3VXJhWU4tY0d5M0xwbzk3anRVaHFIWVBQQ2FjbFlBVU8xc2ZmM0w2YlhqMGM0Mm9OT0hOaTBveU9XZGFETGRw?oc=5","date":"2017-03-06","type":"deal","source":"Pharmafile","summary":"Otsuka to acquire Neurovance in potential $250 million deal - Pharmafile","headline":"Otsuka to acquire Neurovance in potential $250 million deal","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimAFBVV95cUxQZnMxZmRzamZVMWtsMENuUzEzUXUzeEc2WlZjY3dkOWUzU1dPX2FCdTRSRDN2ZmUyRkhES2w0Rjc1cEZUX2VBSTNHUWo1TUZocDdid3MwNXJhT0xpNTBUZ2JkTFV6N1M2bTduLWFvdmVGNXRCaXVFd0NlS2FuQUhYekxZSVo1SGhiT2NwZHhHZlVBcFhtZ3VkTg?oc=5","date":"2014-08-08","type":"trial","source":"drugdiscoverytrends.com","summary":"Neurovance Completes Enrollment in Abuse Liability Study - drugdiscoverytrends.com","headline":"Neurovance Completes Enrollment in Abuse Liability Study","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_1":1},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}